Most recently, highly valuable mechanistical insights into BCL-2 family interactions enabled the development of cancer therapies, including the bona fide BH3-mimetic drugs (Navitoclax), a highly selective BCL-2 inhibitor (Venetoclax), and MCL-1 inhibitors.12, 13, 14 In addition to their therapeutical use, BH3 profiling of tumors has also been proposed as a 'biomarker' strategy for the prediction of chemotherapy sensitivity.15, 16, 17 Dissecting the mechanisms underlying apoptosis will allow us to exploit programmed cell death for the treatment of human diseases. Here, BCL2 is linked to cancer.